drugset
Drugs / 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester
last change May 2026 re-read 3 minutes ago

3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester

Developed for
gliosarcoma
Investigated by
National Cancer Institute (NCI) · Photolitec LLC · Roswell Park Cancer Institute

Trials 1

today NCT05363826 · Ph 1
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05363826 Apr 2023 → May 2025 gliosarcoma Photolitec LLC Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester ClinicalTrials.gov intervention name — accepted as the source's own label NCT05363826 ↗